Neuvivo is a late-clinical stage biopharmaceutical company developing new treatments for ALS and other neurodegenerative diseases. The company was formed by industry leaders and scientists with the goal of improving the prognosis for patients diagnosed with diseases for which there are few current treatment options. Lead candidate NP001 has shown promise to be effective in a large subset of people living with ALS, coupled with an excellent safety profile. Neuvivo is working to make this treatment broadly available to patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/15/23 | $11,000,000 | Venture |
PrimeStreet Capital | undisclosed |
